Ces radiol. 2012, 66(4):379-385

Changes of the osteoblastic activity on 18F-NaF-PET/CT in patients with treated prostatic carcinomaOriginal article

Eva Ferdová1, Jiří Ferda1, Jindřich Fínek2, Luboš Holubec jr.2, Boris Kreuzberg1
1 Klinika zobrazovacích metod LF UK a FN, Plzeň
2 Onkologické a radioterapeutické oddělení LF UK a FN, Plzeň

Aim: To evaluate the possibilities in the assessment of the consequences of antiandrogen therapy in men with treated prostatic carcinoma during the evaluation of 18F-NaF-PET/CT.

Method: In 30 consecutive examinations of 18F-NaF-PET/CT in men with treated prostatic carcinoma were assessed the changes in the osteoblastic activity like high-turnover osteopenia, and especially the changes related to the insufficiency fractures. All examinations were conducted after intravenous application of 18F-NaF in the dose of 2 MBq/kg during the steady-state period of radiopharmaceutical distribution, all CT scans were performed with low-dose protocol, without application of kosine kontrast materiál a nd with submillimeter spatial resolution.

Results: In 3 patients, the signs of high-turnover osteopenia were found, the all of patients were on relative short-term antiandrogen therapy. In 3 patients, the insufficiency fractures were found, twice in pelvic girdle, once rib fractures. In 8 men, the increased osteoblastic activity was found within weight bearing zones; the degenerative changes with active bone turn over in 4 men respectively.

Conclusion: 18F-NaFPET/CT is the important diagnostic tool which is able to detect the changes of the osteoblastic activity inn patients under antiandrogen therapy and also it is able to detect insufficiency pelvic fractures caused by accelerated osteoporosis.

Keywords: antiandrogen therapy, prostatic carcinoma insufficiency fractures, 18F-NaF-PET, CT
Grants and funding:

Práce podpořena Programem rozvoje Univerzity Karlovy (projekt číslo P36).

Accepted: August 15, 2012; Published: December 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ferdová E, Ferda J, Fínek J, Holubec L, Kreuzberg B. Changes of the osteoblastic activity on 18F-NaF-PET/CT in patients with treated prostatic carcinoma. Ces radiol. 2012;66(4):379-385.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Li Y, Schiepers C, Lake R, Dadparvar S, Berenji GR. Clinical utility of (18)F-fluoride PET/CT in benign and malignant bone diseases. Bone 2012; 50(1): 128-139. Epub 2011 Oct 6. Review. Go to original source... Go to PubMed...
    2. Bortot DC, Amorim BJ, Oki GC, et al. (18)F-Fluoride PET/CT is highly effective for excluding bone metastases even in patients with equivocal bone scintigraphy. Eur J Nucl Med Mol Imaging 2012; 39(11): 1730-1736. Go to original source... Go to PubMed...
    3. Withofs N, Grayet B, Tancredi T et al. 18F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers. Nucl Med Commun 2011; 32(3): 168-176. Go to original source... Go to PubMed...
    4. Nishiyama Y, Tateishi U, Shizukuishi K, et al. Role of (18)F-fluoride PET/CT in the assessment of multiple myeloma: initial experience. Ann Nucl Med 2012 [Epub ahead of print]. PubMed PMID: 22914967. Go to original source... Go to PubMed...
    5. Fischer DR, Pfirrmann CW, Zubler V, et al. High bone turnover assessed by 18F-fluoride PET/CT in the spine and sacroiliac joints of patients with ankylosing spondylitis: comparison with inflammatory lesions detected by whole body MRI. EJNMMI Res 2012; 2(1): 38. doi: 10.1186/2191-219X-2-38. PubMed PMID: 22788874; PubMed Central PMCID: PMC3472173. Go to original source... Go to PubMed...
    6. Langsteger W, Balogova S, Huchet V, et al. Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading. Q J Nucl Med Mol Imaging 2011; 55(4): 448-457.
    7. Nagarajah J, Dannat T, Hartung V, Bockisch A, Rosenbaum-Krumme S. 18F-fluoride PET/CT for bone scanning. Role of attenuation correction. Nuklearmedizin 2012; 51(3): 84-87. Go to original source... Go to PubMed...
    8. Chen CJ, Ma SY. Prevalence of Clinically Significant Extraosseous Findings on Unenhanced CT Portions of (18) F-Fluoride PET/CT Bone Scans. ScientificWorldJournal. 2012; 2012:979867 [Epub 2012 Sep 10]. PubMed PMID: 22997503; PubMed Central PMCID: PMC3446638. Go to original source... Go to PubMed...
    9. Chan SC, Wang HM, Ng SH, et al. Utility of 18F-Fluoride PET/CT and 18F-FDG PET/CT in the Detection of Bony Metastases in Heightened-Risk Head and Neck Cancer Patients. J Nucl Med 2012 [E-pub ahead of print]. PubMed PMID: 22961077. Go to original source... Go to PubMed...
    10. Dua SG, Purandare NC, Shah S, Rangarajan V. F-18 fluoride PET/CT in the detection of radiation-induced pelvic insufficiency fractures. Clin Nucl Med 2011; 36(10): e146-149. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content